Naquin Ethan R, Garg Richa, Chen William J, Karmakar Eshani, Prasad Amogh, Mandadi Saicharan, Depala Kiran, Gopianand Jyotsna S, Gnana-Prakasam Jaya P
Department of Ophthalmology, School of Medicine, Saint Louis University, Saint Louis, MO 63104, USA.
Nutrients. 2025 Sep 16;17(18):2964. doi: 10.3390/nu17182964.
Iron is an essential micronutrient integral to ocular physiology, supporting biochemical processes such as mitochondrial respiration, DNA synthesis and phototransduction. Disruptions in systemic or local iron homeostasis, whether due to overload or deficiency, have been increasingly implicated in the pathogenesis of a broad range of anterior and posterior segment ocular disorders. Iron deficiency may compromise retinal bioenergetics, impair cellular repair, and increase susceptibility to oxidative stress, while iron overload facilitates the generation of reactive oxygen species, contributing to lipid peroxidation, mitochondrial dysfunction, and ferroptosis. Dysregulated iron metabolism has been associated with several ocular pathologies, including age-related macular degeneration, diabetic retinopathy, glaucoma, retinal detachment, cataracts, and anemic retinopathy. The eye possesses specialized iron regulatory mechanisms involving proteins such as transferrin, ferritin, ferroportin, and hepcidin that govern iron transport, storage, and export across ocular barriers. Aberrations in these pathways are now recognized as contributing factors in disease progression. This narrative review explores the complex dual role of iron overload and deficiency in ocular diseases. It highlights the molecular mechanisms underlying iron-mediated pathologies in both the posterior and anterior segments of the eye, along with the clinical manifestations of iron imbalance. Current therapeutic approaches are discussed, including oral and parenteral iron supplementation for deficiency and emerging chelation-based or antioxidant strategies to address iron overload, while highlighting their limitations. Key challenges remain in developing targeted ocular delivery systems that optimize bioavailability and minimize systemic toxicity. Hence, maintaining iron homeostasis is critical for visual function, and further research is needed to refine therapeutic interventions and clarify the mechanistic role of iron in ocular health and disease.
铁是眼部生理不可或缺的必需微量营养素,支持线粒体呼吸、DNA合成和光转导等生化过程。全身或局部铁稳态的破坏,无论是由于过载还是缺乏,都越来越多地与多种眼前段和眼后段眼部疾病的发病机制相关。缺铁可能会损害视网膜生物能量代谢、阻碍细胞修复并增加对氧化应激的易感性,而铁过载则会促进活性氧的产生,导致脂质过氧化、线粒体功能障碍和铁死亡。铁代谢失调与多种眼部疾病有关,包括年龄相关性黄斑变性、糖尿病视网膜病变、青光眼、视网膜脱离、白内障和贫血性视网膜病变。眼睛拥有专门的铁调节机制,涉及转铁蛋白、铁蛋白、铁转运蛋白和铁调素等蛋白质,这些蛋白质控制着铁在眼部屏障中的运输、储存和输出。现在人们认识到这些途径的异常是疾病进展的促成因素。这篇叙述性综述探讨了铁过载和缺乏在眼部疾病中的复杂双重作用。它强调了眼部前后段铁介导的病理过程的分子机制,以及铁失衡的临床表现。讨论了当前的治疗方法,包括针对缺铁的口服和肠胃外铁补充,以及针对铁过载的新兴螯合或抗氧化策略,同时强调了它们的局限性。在开发优化生物利用度并最小化全身毒性的靶向眼部给药系统方面,仍然存在关键挑战。因此,维持铁稳态对视觉功能至关重要,需要进一步研究以完善治疗干预措施,并阐明铁在眼部健康和疾病中的机制作用。